Takeda's $5.2B Ari­ad deal pays off with a la­bel ex­pan­sion in rare form of leukemia

Take­da’s can­cer drug Iclusig scored an ac­cel­er­at­ed ap­proval in com­bi­na­tion with chemother­a­py from the FDA on Tues­day for new­ly-di­ag­nosed adults with Philadel­phia chro­mo­some-pos­i­tive acute lym­phoblas­tic leukemia (Ph+ ALL).

The ap­proval is the lat­est win to come from Take­da’s $5.2 bil­lion deal to ac­quire Ari­ad Phar­ma­ceu­ti­cals and Iclusig. At the time of the 2017 trans­ac­tion, the drug­mak­er hint­ed at po­ten­tial la­bel ex­pan­sions be­yond its orig­i­nal ap­provals, which date back more than a decade.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER